1400-Mitochondrial-Driven Resistance in Osteosarcoma

Paper Talk · Aug 7, 2026 · 22m

This research article investigates how targeting the C/EBPα/GREM1/p-ERK signaling axis can reverse resistance to doxorubicin in osteosarcoma, a common primary bone cancer. The study identifies GREM1 as a critical regulator that sensitizes tumor cells to chemotherapy by encouraging mitochondrial fission and triggering ROS-induced apoptosis. Researchers discovered that the transcription factor C/EBPα drives GREM1 expression, while the MAPK/ERK pathway acts as a downstream effector that maintains mitochondrial stability in resistant cells. To combat this, the authors utilized a C/EBPα agonist…